{"id":"https://openalex.org/W4253991105","doi":"https://doi.org/10.1182/blood-2019-127390","title":"A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas","display_name":"A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas","publication_year":2019,"publication_date":"2019-11-13","ids":{"openalex":"https://openalex.org/W4253991105","doi":"https://doi.org/10.1182/blood-2019-127390"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2019-127390","doi":"https://doi.org/10.1182/blood-2019-127390","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2019-127390","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"William Pearse","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I111979921","display_name":"Northwestern University","ror":"https://ror.org/000e0be47","country_code":"US","type":"education","lineage":["https://openalex.org/I111979921"]},{"id":"https://openalex.org/I4390039227","display_name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University","ror":"https://ror.org/02p4far57","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210147348","https://openalex.org/I4390039227"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William Pearse","raw_affiliation_strings":["Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL","institution_ids":["https://openalex.org/I111979921","https://openalex.org/I4390039227"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011181925","display_name":"Barbara Pro","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I111979921","display_name":"Northwestern University","ror":"https://ror.org/000e0be47","country_code":"US","type":"education","lineage":["https://openalex.org/I111979921"]},{"id":"https://openalex.org/I4390039227","display_name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University","ror":"https://ror.org/02p4far57","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210147348","https://openalex.org/I4390039227"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Barbara Pro","raw_affiliation_strings":["Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL","institution_ids":["https://openalex.org/I111979921","https://openalex.org/I4390039227"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010130956","display_name":"Leo I. Gordon","orcid":"https://orcid.org/0000-0003-1666-7064","observed_orcids":["https://orcid.org/0000-0003-1666-7064"]},"institutions":[{"id":"https://openalex.org/I111979921","display_name":"Northwestern University","ror":"https://ror.org/000e0be47","country_code":"US","type":"education","lineage":["https://openalex.org/I111979921"]},{"id":"https://openalex.org/I4390039227","display_name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University","ror":"https://ror.org/02p4far57","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210147348","https://openalex.org/I4390039227"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Leo I. Gordon","raw_affiliation_strings":["Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL","institution_ids":["https://openalex.org/I111979921","https://openalex.org/I4390039227"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000227859","display_name":"Reem Karmali","orcid":"https://orcid.org/0000-0003-0984-4376","observed_orcids":["https://orcid.org/0000-0003-0984-4376"]},"institutions":[{"id":"https://openalex.org/I111979921","display_name":"Northwestern University","ror":"https://ror.org/000e0be47","country_code":"US","type":"education","lineage":["https://openalex.org/I111979921"]},{"id":"https://openalex.org/I4390039227","display_name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University","ror":"https://ror.org/02p4far57","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210147348","https://openalex.org/I4390039227"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Reem Karmali","raw_affiliation_strings":["Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL","institution_ids":["https://openalex.org/I111979921","https://openalex.org/I4390039227"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003670546","display_name":"Jane N. Winter","orcid":"https://orcid.org/0000-0001-7542-3305","observed_orcids":["https://orcid.org/0000-0001-7542-3305"]},"institutions":[{"id":"https://openalex.org/I111979921","display_name":"Northwestern University","ror":"https://ror.org/000e0be47","country_code":"US","type":"education","lineage":["https://openalex.org/I111979921"]},{"id":"https://openalex.org/I4390039227","display_name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University","ror":"https://ror.org/02p4far57","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210147348","https://openalex.org/I4390039227"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jane N. Winter","raw_affiliation_strings":["Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL","institution_ids":["https://openalex.org/I111979921","https://openalex.org/I4390039227"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079663967","display_name":"Shuo Ma","orcid":"https://orcid.org/0000-0002-6139-5486","observed_orcids":["https://orcid.org/0000-0002-6139-5486"]},"institutions":[{"id":"https://openalex.org/I111979921","display_name":"Northwestern University","ror":"https://ror.org/000e0be47","country_code":"US","type":"education","lineage":["https://openalex.org/I111979921"]},{"id":"https://openalex.org/I4390039227","display_name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University","ror":"https://ror.org/02p4far57","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210147348","https://openalex.org/I4390039227"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shuo Ma","raw_affiliation_strings":["Division of Hematology / Oncology, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology / Oncology, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL","institution_ids":["https://openalex.org/I111979921","https://openalex.org/I4390039227"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073890024","display_name":"Amir Behdad","orcid":"https://orcid.org/0000-0002-3944-2792","observed_orcids":["https://orcid.org/0000-0002-3944-2792"]},"institutions":[{"id":"https://openalex.org/I111979921","display_name":"Northwestern University","ror":"https://ror.org/000e0be47","country_code":"US","type":"education","lineage":["https://openalex.org/I111979921"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amir Behdad","raw_affiliation_strings":["Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL","institution_ids":["https://openalex.org/I111979921"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062249687","display_name":"Andreas K. Klein","orcid":"https://orcid.org/0000-0002-2559-8139","observed_orcids":["https://orcid.org/0000-0002-2559-8139"]},"institutions":[{"id":"https://openalex.org/I1290900354","display_name":"Tufts Medical Center","ror":"https://ror.org/002hsbm82","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1290900354"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andreas Klein","raw_affiliation_strings":["Hematology/Oncology, Tufts Medical Center, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology/Oncology, Tufts Medical Center, Boston, MA","institution_ids":["https://openalex.org/I1290900354"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068449176","display_name":"Adam Matthew Petrich","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I111979921","display_name":"Northwestern University","ror":"https://ror.org/000e0be47","country_code":"US","type":"education","lineage":["https://openalex.org/I111979921"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Adam M. Petrich","raw_affiliation_strings":["Northwestern Univeristy, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Northwestern Univeristy, Chicago, IL","institution_ids":["https://openalex.org/I111979921"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108515350","display_name":"Borko D. Jovanovic","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I111979921","display_name":"Northwestern University","ror":"https://ror.org/000e0be47","country_code":"US","type":"education","lineage":["https://openalex.org/I111979921"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Borko Jovanovic","raw_affiliation_strings":["Department of Preventive Medicine, Northwestern University, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Preventive Medicine, Northwestern University, Chicago, IL","institution_ids":["https://openalex.org/I111979921"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005159945","display_name":"Sonali M. Smith","orcid":"https://orcid.org/0000-0002-9893-4949","observed_orcids":["https://orcid.org/0000-0002-9893-4949"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sonali M. Smith","raw_affiliation_strings":["Section of Hematology/Oncology, University of Chicago, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Section of Hematology/Oncology, University of Chicago, Chicago, IL","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5104729869","display_name":"Andrew G. Evans","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I28792581","display_name":"University of Rochester Medicine","ror":"https://ror.org/00trqv719","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I28792581","https://openalex.org/I5388228"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew G Evans","raw_affiliation_strings":["University of Rochester Medical Center, Rochester, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Rochester Medical Center, Rochester, NY","institution_ids":["https://openalex.org/I28792581"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":6,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"134","issue":"Supplement_1","first_page":"351","last_page":"351"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10685","display_name":"Viral-associated cancers and disorders","score":0.8554999828338623,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10685","display_name":"Viral-associated cancers and disorders","score":0.8554999828338623,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.13920000195503235,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11811","display_name":"Cutaneous lymphoproliferative disorders research","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/brentuximab-vedotin","display_name":"brentuximab vedotin","score":0.9269999861717224},{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":1.0},{"id":"https://openalex.org/keywords/cd30-positive-lymphoma","display_name":"CD30-positive lymphoma","score":0.8629999756813049},{"id":"https://openalex.org/keywords/epstein-barr-virus-associated-lymphoma","display_name":"Epstein-Barr virus-associated lymphoma","score":0.9020000100135803},{"id":"https://openalex.org/keywords/post-transplant-lymphoproliferative-disorder","display_name":"post-transplant lymphoproliferative disorder","score":0.8970000147819519},{"id":"https://openalex.org/keywords/solid-organ-transplant-recipients","display_name":"solid organ transplant recipients","score":0.781000018119812},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.652999997138977},{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.8930000066757202},{"id":"https://openalex.org/keywords/maintenance-therapy","display_name":"maintenance therapy","score":0.621999979019165},{"id":"https://openalex.org/keywords/consolidation-therapy","display_name":"consolidation therapy","score":0.718999981880188},{"id":"https://openalex.org/keywords/treatment-related-mortality","display_name":"non-relapse mortality","score":0.5929999947547913},{"id":"https://openalex.org/keywords/graft-rejection","display_name":"graft rejection","score":0.4350000023841858},{"id":"https://openalex.org/keywords/regulatory-t-cells","display_name":"regulatory T cells","score":0.6520000100135803},{"id":"https://openalex.org/keywords/cd20","display_name":"CD20","score":0.4410000145435333}],"concepts":[{"id":"https://openalex.org/C2778191690","wikidata":"https://www.wikidata.org/wiki/Q422324","display_name":"Brentuximab vedotin","level":4,"score":0.8039137125015259},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.801720142364502},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.5883099436759949},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5734950304031372},{"id":"https://openalex.org/C2780252810","wikidata":"https://www.wikidata.org/wiki/Q1455316","display_name":"Immunosuppression","level":2,"score":0.5612033009529114},{"id":"https://openalex.org/C70905583","wikidata":"https://www.wikidata.org/wiki/Q3648608","display_name":"CD30","level":3,"score":0.5554611086845398},{"id":"https://openalex.org/C2780790343","wikidata":"https://www.wikidata.org/wiki/Q5090610","display_name":"Chemoimmunotherapy","level":4,"score":0.5172584652900696},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5132629871368408},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4602595269680023},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.4451201260089874},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.43600988388061523},{"id":"https://openalex.org/C2776995267","wikidata":"https://www.wikidata.org/wiki/Q4165484","display_name":"Lymphoproliferative disorders","level":3,"score":0.4170815944671631},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.40495091676712036},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2019-127390","doi":"https://doi.org/10.1182/blood-2019-127390","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2019-127390","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2991519754","https://openalex.org/W2559295956","https://openalex.org/W3190895587","https://openalex.org/W4389243525","https://openalex.org/W3025072273","https://openalex.org/W3094835741","https://openalex.org/W3141376286","https://openalex.org/W2765568148","https://openalex.org/W3094834216","https://openalex.org/W4310107674"],"abstract_inverted_index":{"Background:":[0],"Immunocompromised":[1],"patients":[2],"(pts)":[3],"face":[4],"an":[5,117,139,574,792,803],"approximate":[6],"6-fold":[7],"increase":[8],"in":[9,188,212,365,424,581,715,717],"lifetime":[10],"risk":[11,77],"of":[12,23,34,49,58,66,78,91,102,114,162,172,196,207,224,243,267,308,327,344,355,360,427,441,446,451,467,516,526,552,569,599,627,641,648,795,806],"lymphoid":[13,220,422],"malignancies":[14,423],"compared":[15,174,620],"with":[16,175,215,251,258,277,621],"immunocompetent":[17],"counterparts.":[18],"Additionally,":[19],"up":[20,323],"to":[21,87,120,184,296,303,324,419,481,499,506,529,609,635,657,663,732],"80%":[22,43],"post-transplant":[24],"lymphoproliferative":[25],"disease":[26,260,274],"(PTLD)":[27],"cases":[28],"are":[29,74,372,655],"driven":[30],"by":[31,99,248,272,289],"EBV-associated":[32,421],"mechanisms":[33],"tumorigenesis.":[35],"Approximately":[36],"70%":[37],"will":[38,44],"express":[39,45],"CD30":[40],"and":[41,61,123,154,164,170,186,205,234,315,335,349,353,369,384,414,459,474,501,522,545,561,578,592,603,615,644,662,669],"over":[42,597],"CD20.":[46],"Recent":[47],"studies":[48,654],"chemoimmunotherapy":[50],"(CIT)":[51],"have":[52,420,605],"reported":[53],"median":[54,444],"overall":[55],"survival":[56,453,614],"(OS)":[57],"2-4":[59],"years":[60,381,463],"treatment-related":[62],"mortality":[63],"(TRM)":[64],"rates":[65],"13-50%.":[67],"Moreover,":[68],"solid":[69],"organ":[70],"transplant":[71],"(SOT)":[72],"pts":[73,115,181,213,362,386,394,407,416,488,494,509,600,628],"at":[75,341,454,461,471],"significant":[76],"graft":[79],"rejection":[80],"when":[81,585],"CIT":[82],"is":[83,138],"employed,":[84],"possibly":[85],"due":[86,528,634],"\"off":[88],"target\"":[89],"depletion":[90],"regulatory":[92],"T-cell":[93,152],"populations.":[94],"R":[95,121,165,176,225,316,572],"monotherapy":[96,177],"induction,":[97,178,345,492],"followed":[98,247,271,288],"response-stratified":[100],"use":[101],"CIT,":[103,185],"has":[104],"been":[105,606],"evaluated":[106],"(Trappe,":[107],"et":[108],"al,":[109],"JCO,":[110],"2016).":[111],"However,":[112,624],"~75%":[113],"had":[116,396,573],"inadequate":[118],"response":[119,173,279,282,336,370,433,483],"alone":[122],"required":[124,408,511,524],"subsequent":[125,182],"CIT;":[126],"2-yr":[127],"OS":[128,468],"for":[129,148,322,374,410,590],"the":[130,203,342,366,425,449,642],"population":[131],"as":[132,209,587],"a":[133,160,197,244,399,438],"whole":[134],"was":[135,301,330,339,379,435,457,469,484,504],"~70%.":[136],"BV":[137,163,235,309,570],"anti-CD30":[140],"antibody-drug":[141],"conjugate":[142],"that":[143,159,645],"received":[144,397],"accelerated":[145],"FDA":[146],"approval":[147],"previously":[149],"untreated":[150],"CD30+":[151,217],"lymphoma":[153],"Hodgkin":[155],"lymphoma.":[156],"We":[157,192],"hypothesized":[158],"combination":[161,568],"would":[166,179],"yield":[167],"improved":[168],"breadth":[169],"depth":[171],"spare":[180],"exposure":[183,608],"result":[187],"favorable":[189],"OS.":[190],"Methods:":[191],"report":[193],"here":[194],"results":[195,661],"phase":[198],"I/II":[199],"multicenter":[200],"study":[201,263],"investigating":[202],"efficacy":[204,660],"safety":[206,576],"BV+R":[208,666],"frontline":[210,588],"therapy":[211,291,521,527,589,630,649],"diagnosed":[214],"immunosuppression-associated":[216],"and/or":[218],"EBV+":[219],"malignancies.":[221],"Induction":[222],"consisted":[223,307],"375":[226,317],"mg/m2":[227,318],"given":[228,238],"days":[229,239],"1,":[230,240],"8,":[231,241],"15,":[232,242],"22":[233,361],"1.2":[236],"mg/kg":[237,311],"28-day":[245],"cycle,":[246],"restaging.":[249],"Those":[250],"progression":[252],"were":[253,261,363,388,417,540,555,618],"removed":[254],"from":[255],"study.":[256],"Pts":[257,276],"stable":[259],"offered":[262],"discontinuation":[264,525],"or":[265,280,293,401,514,797,808],"completion":[266],"one":[268],"consolidation":[269,287,346],"cycle":[270],"repeat":[273],"assessment.":[275],"partial":[278],"complete":[281],"(CR)":[283],"could":[284],"receive":[285],"either":[286,398],"maintenance":[290],"(MT)":[292],"move":[294],"directly":[295],"MT":[297,306],"without":[298],"consolidation.":[299],"Consolidation":[300],"identical":[302],"induction":[304,520],"dosing;":[305],"1.8":[310],"every":[312,319],"3":[313,406,415,462],"weeks":[314,321],"6":[320],"1":[325,455,502,532,632],"year":[326,456,633],"therapy.":[328],"Toxicity":[329,368],"defined":[331],"using":[332],"CTCAE":[333],"4.0":[334],"(Cheson,":[337],"2007)":[338],"assessed":[340],"end":[343],"(if":[347],"given),":[348],"after":[350,491],"cycles":[351],"4":[352],"7":[354],"BV.":[356],"Results:":[357],"A":[358],"total":[359],"entered":[364],"trial.":[367],"data":[371,617],"available":[373],"20":[375],"pts.":[376],"Median":[377,479],"age":[378],"67":[380],"(range,":[382,390],"30-79)":[383],"14":[385],"(64%)":[387,395],"male":[389],"30-79":[391],"years).":[392],"Fourteen":[393],"SOT":[400],"hematopoietic":[402],"allograft":[403],"requiring":[404],"immunosuppression,":[405],"immunosuppression":[409,429],"underlying":[411],"rheumatologic":[412],"conditions,":[413],"found":[418],"absence":[426],"iatrogenic":[428],"(Table":[430,564],"1).":[431,465,478],"Overall":[432],"rate":[434,440],"70%,":[436],"including":[437],"CR":[439],"60%.":[442],"With":[443],"follow-up":[445,476],"26.1":[447],"month,":[448],"probability":[450],"progression-free":[452],"75.2%":[458],"67.6%":[460],"(Fig":[464,477],"Probability":[466],"89.2%":[470],"both":[472],"1-year":[473],"3-year":[475],"time":[480],"best":[482],"28":[485],"days.":[486],"Three":[487],"withdrew":[489],"consent":[490],"2":[493],"died":[495],"(1":[496],"death":[497],"related":[498],"treatment),":[500],"patient":[503],"lost":[505],"follow-up.":[507],"Seven":[508],"(31%)":[510],"dose":[512],"adjustments":[513],"delay":[515],"medication":[517],"administration":[518],"during":[519],"45%":[523],"toxicity":[530,636],"within":[531,631],"year.":[533],"The":[534,547,567],"most":[535,548],"frequent":[536,549],"grade":[537,554],"3/4":[538],"toxicities":[539],"peripheral":[541,562],"neuropathy,":[542],"neutropenia,":[543],"lymphopenia,":[544],"pancreatitis.":[546],"adverse":[550],"events":[551],"any":[553],"fatigue,":[556],"nausea,":[557],"abdominal":[558],"pain,":[559],"pancytopenia,":[560],"neuropathy":[563],"2).":[565],"Conclusions:":[566],"+":[571],"acceptable":[575],"profile":[577],"appeared":[579],"effective":[580],"achieving":[582],"early":[583],"remissions":[584],"used":[586],"PTLD":[591],"other":[593],"immunosuppression-related":[594],"lymphomas.":[595],"Specifically,":[596],"half":[598,626],"achieved":[601],"CR,":[602],"75%":[604],"spared":[607],"multi-agent":[610],"cytotoxic":[611],"chemotherapy.":[612],"Furthermore,":[613],"PFS":[616],"encouraging":[619],"historical":[622],"controls.":[623],"nearly":[625],"discontinued":[629],"suggesting":[637],"poor":[638],"long-term":[639],"tolerance":[640],"regimen":[643],"earlier":[646],"cessation":[647],"may":[650],"be":[651],"warranted.":[652],"Further":[653],"needed":[656],"confirm":[658],"these":[659],"determine":[664],"optimal":[665],"dosing":[667],"regimens":[668],"durations.":[670],"Disclosures":[671],"Pro:":[672],"Seattle":[673],"Genetics:":[674],"Consultancy,":[675,683,689,694,721,735,740,754,762],"Honoraria,":[676,684],"Other:":[677,685,697,701,705,712,729,786],"Travel":[678,686],"Expenses,":[679],"Research":[680,708,730,736,741,746,751,755,768,771,774,777,780,783,817],"Funding;":[681,709,747,752,769,772,775,778,781],"Takeda:":[682],"Expenses;":[687],"Celgene:":[688],"Honoraria;":[690],"Kyowa":[691],"Hakka":[692],"Kirin:":[693],"Honoraria.":[695],"Gordon:Gilead:":[696],"Advisory":[698,702,706],"Board;":[699,703],"Bayer:":[700],"Juno/Celgene:":[704,720],"Board,":[707],"Zylem":[710],"LLC:":[711],"co-founder;":[713],"research":[714],"nanoparticles":[716],"cancer.":[718],"Karmali:Gilead/Kite;":[719],"Speakers":[722,725,743,757,763],"Bureau;":[723,726,744,758,764],"Astrazeneca:":[724],"Takeda,":[727],"BMS:":[728],"Funding":[731],"Institution.":[733],"Winter:Merck:":[734],"Funding.":[737,784,818],"Ma:Astra":[738],"Zeneca:":[739],"Funding,":[742,756],"Xeme:":[745],"Bioverativ:":[748],"Consultancy;":[749,760,766],"Beigene:":[750],"Pharmacyclics:":[753],"Kite:":[759],"Janssen:":[761],"Genentech:":[765],"Abbvie:":[767],"Incyte:":[770],"Juno:":[773],"Acerta:":[776],"Gilead:":[779],"Novartis:":[782],"Behdad:Pfizer:":[785],"Speaker;":[787],"Thermo":[788],"Fisher:":[789],"Membership":[790,801],"on":[791,802],"entity's":[793,804],"Board":[794,805],"Directors":[796,807],"advisory":[798,809],"committees;":[799],"Loxo-Bayer:":[800],"committees.":[810],"Petrich:AbbVie:":[811],"Employment,":[812],"Equity":[813],"Ownership.":[814],"Smith:Portola":[815],"Pharmaceuticals:":[816]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":1}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2022-05-12T00:00:00"}